Elevation Oncology, Inc.

ELEV

US28623U1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
2.85 ^USD	+5.56%		+5.56%	+430.73%

07-01	Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell Small Cap Comp Value Index	CI
07-01	Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell Small Cap Completeness Index	CI

Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 2500 Index

July 30, 2024

Latest news about Elevation Oncology, Inc.

Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell Small Cap Comp Value Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell Small Cap Completeness Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 3000 Value Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 2000 Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 3000E Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 2500 Growth Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 2500 Value Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 3000E Growth Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 3000 Growth Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 2000 Value Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 2000 Growth Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 2000 Dynamic Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell Small Cap Comp Growth Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 2500 Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 3000 Index	06-30	CI
Elevation Oncology, Inc.(NasdaqGS:ELEV) added to Russell 3000E Value Index	06-30	CI
Elevation to Assess EO-3021 in Drug Combinations to Treat Gastric or Gastroesophageal Junction Cancer	06-27	MT
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer	06-27	CI
Piper Sandler Starts Elevation Oncology With Overweight Rating, $10 Price Target	05-31	MT
Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target	05-14	MT
Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Elevation Oncology, Inc. Announces Management Changes	04-05	CI
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	03-27	MT
Wedbush Raises Elevation Oncology's PT to $8 From $5, Continues to See 'Intriguing' Opportunity in Shares; Keeps Outperform Rating	03-07	MT
Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-06	CI

Chart Elevation Oncology, Inc.

Duration

Period

More charts

Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.85 USD

Average target price

8.167 USD

Spread / Average Target

+186.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ELEVATION ONCOLOGY, INC.	+430.73%	156M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.56B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs